Maria Greenwald
Rancho Mirage, CANPI 1003899758
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $940 of the $1,277 with a category attached, or 73.6%. Pfizer accounts for 91.4% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $1,021 and has fallen 96.2% since, to $39 in 2025.
Across 16 payments — averaging $79.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- Johnson & Johnson$70
- AbbVie$14
- Novartis$13
- Karyopharm Therapeutics Inc.$12
Across 534 payments — averaging $11,046 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.7M
- Gilead$837K
- AbbVie$812K
- Pfizer$434K
- Novartis$401K
- Amgen$323K
- plus $378K from 5 others
What the payments were for
- Speaking & faculty fees$94074%
- Food & beverage$25420%
- Education$826%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 11 | $1,167 |
| Johnson & Johnson | 1 | $70 |
| AbbVie | 2 | $14 |
| Novartis | 1 | $13 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XELJANZ$940
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EnbrelEtanercept | 12 | $83,517 |
| MethotrexateMethotrexate Sodium | 13 | $417 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.